Secondary dysmyelopoiesis in patients with myelodysplastic syndromes: A review of literature and the authors' data


Cite item

Full Text

Abstract

To interpret hematopoietic cell myelodysplastic changes found during the primary diagnosis of myelodysplastic syndromes or other diseases and during therapy is an enormously complex clinical and laboratory problem. In what cases do these changes serve as a manifestation of clonal disease and in what cases are these changes a result of various effects? Alimentary, toxic factors, infectious agents, and iatrogenic effects may cause myelodysplastic signs in the hematopoietic cells. This review depicts diverse hematopoietic cell dysplastic changes that can be observed as a result of the effects of one drug or another, toxic factors, and infectious agents.

Full Text

Вторичный дисмиелопоэз у больных миелодиспластическими синдромами. - Аннотация. Трактовка миелодиспластических изменений кроветворных клеток, обнаруженных при первичной диагностике миелодиспластических синдромов или других заболеваний и в процессе терапии, является исключительно сложной клинико-лабораторной задачей. В каких случаях эти изменения служат проявлением клонального заболевания, а в каких - следствием разнообразных воздействий? Алиментарные, токсичные факторы, инфекционные агенты, а также ятрогенные воздействия могут быть причиной появления миелодиспластических признаков в кроветворных клетках. В настоящем обзоре описаны разнообразные диспластические изменения кроветворных клеток, которые можно наблюдать как результат влияния тех или иных лекарственных препаратов, токсичных факторов, инфекционных агентов.
×

References

  1. Swerdlow S.H. Campo E., Harris N.L. et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARS-press 2008; 439.
  2. Schmitz L.L., McClure J.S., Litz C.E. et al. Morphologic and quantitave changes in blood and marrow cells following growth factor therapy. Am О Сlin Pathol 1994; 101: 67-75.
  3. Scott J.M., Weir D.G. Drug-induced megaloblastic change. Clin Haematol 1980; 9 (3): 587-606.
  4. Lindenbaum J. Drugs and vitamin B12 and folate metabolism. Curr Concepts Nutr 1983; 12: 73-87.
  5. Bielenberg J. Folic acid and vitamin deficiency caused by oral contraceptives. Med Monatsschr Pharm 1991; 14 (8): 244-247.
  6. Piso R.J., Kriz K., Desax M.-C. Severe isoniazid related sideroblastic anemia. Hematol Rep 2011; 3 (1): 3-4.
  7. Sharp R.A., Lowe J.G., Johnston R.N. Antituberculous drugs and sideroblastic anaemia. Br J Clin Pract 1990; 44: 706-707.
  8. Yoshimoto S., Takeuchi M., Tada A. Secondary sideroblastic anemia caused by long term administration of anti-tuberculous agents including isoniazid]. Rinsho Ketsueki 1992; 33: 986-990.
  9. Girdwood R.H. Drug-induced anaemias. Drugs 1976; 11 (5): 394-404.
  10. Gregg K.T., Reddy V., Prchal J.T. Cooper deficiency masquerading as myelodysplastic syndrome. Blood 2002; 100 (4): 1493-1495.
  11. Huff J.D., Keung Y.K., Thakuri M. et al. Am J Hematol 2007; 82 (7): 625-630.
  12. Heidemann E., Nerke O., Waller H.D. Alcohol induced changes in hemopoiesis. Klin Wochenschr 1981; 59 (23): 1303-1312.
  13. Casagrande G., Michot F. Alcohol-induced bone marrow damage: status before and after a 4-week period of abstinence from alcohol with or without disulfiram. A randomized bone marrow study in alcohol-dependent individuals. Blut 1989; 59 (3): 231-236.
  14. Hellerich U., Budde R. Toxic alcohol dysmyelopoiesis - bone marrow histology studies of a forensic medicine autopsy sample. Beitr Gerichtl Med 1992; 50: 69-74.
  15. Latvala J., Parkkila S., Niemelä O. Excess alcohol consumption is common in patients with cytopenia: studies in blood and bone marrow cells. Alcohol Clin Exp Res 2004; 28 (4): 619-624.
  16. Niemelä O., Parkkila S. Alcoholic macrocytosis - is there a role for acetaldehyde and adducts? Addict Biol 2004; 9 (1): 3-10.
  17. Hoffmann K., Dreger C.K., Olins A.L. et al. Mutations in the gene encoding the lamin B receptor produce an altered nuclear morphology in granulocytes (Pelger-Huёt anomaly). Nat Genet 2002; 31: 410-414.
  18. Pelger K. Demonstrate van een paar zeldzaam voorkomende typen van bloedlichaampjes en bespreking der patienten. Ned Tijdschr Geneeskd 1928; 72: 1178.
  19. Huёt G.J. Familiaire anomalie der leucocyten. Ned Tijdschr Geneeskd 1931; 75: 5956-5959.
  20. Speeckaert M.M., Verhelst C., Koch A. et al. Pelger-Huёt anomaly: a critical review of the literature. Acta Haematol 2009; 121: 202-206.
  21. Cunningham J.M., Patnaik M.M., Hammerschmidt D.E. et al. Historical perspective and clinical implications of the Pelger-Hьet cell. Am J Hematol 2009; 84: 116-119.
  22. Cunningham I., MacCallum S.J., Nicholls M.D. et al. The myelodysplastic syndromes: an analysis of prognostic factors in 226 cases from a single institution. Br J Haematol 1995; 90: 602-606.
  23. Kuriyama K., Tomonaga M., Matsuo T. et al. Diagnostic significance of detecting pseudo-Pelger-Huёt anomalies and micro-megakaryocytes in myelodysplastic syndrome. Br J Haematol 1986; 63: 665-669.
  24. Germing U., Strupp C., Giagounidis A. Detalied morphologic finding in 2773 patients with myelodysplastic syndromes. Leuk Res 2009; 33: 34.
  25. Juneja S.K., Matthews J.P., Luzinat R. et al. Association of acquired Pelger-Huёt anomaly with taxoid therapy. Br J Haematol 1996; 93: 139-141.
  26. Teshima T., Shibuya T., Harada M. et al. Effects of G-CSF, GM-CSF, and IL-5 on nuclear segmentation of neutrophils and eosinophils in congenital or acquired Pelger-Huёt anomaly. Exp Hematol 1991; 19: 322-325.
  27. Moreira A.M., Vieira L.M., Rios D.R. et al. Acquired Pelger-Huёt anomaly associated with ibuprofen therapy [letter] [published correction appears in Clin Chim Acta. 2010; 411: 1397]. Clin Chim Acta 2009; 409: 140-141.
  28. Kaplan J.M., Barrett O. Jr. Reversible pseudo-Pelger anomaly related to sulfisoxazole therapy. N Engl J Med 1967; 277: 421-422.
  29. Levin J.M. Pelger-Huёt anomaly and d-penicillamine [letter]. J Rheumatol 1980; 7: 418-419.
  30. Wang E., Boswell E., Siddiqi I. et al. Pseudo-Pelger-Huёt Anomaly Induced by Medications. A Clinicopathologic Study in Comparison With Myelodysplastic Syndrome-Related Pseudo-Pelger-Huёt Anomaly. Am J Clin Pathol 2011; 135: 291-303.
  31. Etzell J.E., Wang E. Acquired Pelger-Huёt anomaly in association with concomitant tacrolimus and mycophenolate mofetil in a liver transplant patient: a case report and review of the literature. Arch Pathol Lab Med 2006; 130: 93-96.
  32. Asmis L.M., Hadaya K., Majno P. et al. Acquired and reversible Pelger-Huёt anomaly of polymorphonuclear neutrophils in three transplant patients receiving mycophenolate mofetil therapy. Am J Hematol 2003; 73: 244-248.
  33. Kennedy G.A., Kay T.D., Johnson D.W. et al. Neutrophil dysplasia characterised by a pseudo-Pelger-Huёt anomaly occurring with the use of mycophenolate mofetil and ganciclovir following renal transplantation: a report of five cases. Pathology 2002; 34: 263-266.
  34. Gondo H., Okamura C., Osaki K. et al. Acquired Pelger-Huёt anomaly in association with concomitant tacrolimus and fluconazole therapy following allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 26: 1255-1257.
  35. Taegtmeyer A., Halil O., Bell A. et al. Neutrophil dysplasia (acquired pseudo-pelger anomaly) caused by ganciclovir. Transplantation 2005; 80 (1): 127-130.
  36. Gondo H., Okamura C., Osaki K. et al. Acquired Pelger-Huёt anomaly in association with concomitant tacrolimus and fluconazole therapy following allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 26: 1255-1257.
  37. Teshima T., Shibuya T., Harada M. et al. Effects of G-CSF, GM-CSF, and IL-5 on nuclear segmentation of neutrophils and eosinophils in congenital or acquired Pelger-Huёt anomaly. Exp Hematol 1991; 19: 322-325.
  38. Cicchitto G., Parravicini M., De Lorenzo S. et al. Tuberculosis and Pelger-Huёt anomaly: case report. Panminerva Med 1999; 41: 367-369.
  39. Rosell Arnold E., Rodrіguez Miguélez J.M., Roquer González J.M. et al. Reversible Pelger-Huёt anomaly associated with acute gastroenteritis caused by salmonella group D [in Spanish]. An Esp Pediatr 1989; 30: 143-144.
  40. van Hook L., Spivack C., Duncanson F.P. Acquired Pelger-Huёt anomaly associated with Mycoplasma pneumoniae pneumonia. Am J Clin Pathol 1985; 84: 248-251.
  41. Speeckaert M.M., Verhelst C., Koch A. et al. Pelger-Huёt anomaly: a critical review of the literature. Acta Haematol 2009; 21: 202-205.
  42. Рудницкая Ю.В., Морозова Е.В., Мамаев Н.Н. и др. Аллогенная трансплантация гемопоэтических стволовых клеток крови с использованием режимов кондиционирования со сниженной интенсивностью у пациентов с миелодиспластическим синдромом. Клин онкогематол 2011; 3: 196-200.
  43. Wang E., Boswell E., Siddiqi I. et al. Pseudo-Pelger-Huёt Anomaly Induced by Medications. A Clinicopathologic Study in Comparison With Myelodysplastic Syndrome-Related Pseudo-Pelger-Huёt Anomaly. Am J Clin Pathol 2011; 135: 291-303.
  44. Клясова Г.А. Профилактика и лечение инфекционных осложнений. Руководство по гематологии. Под ред. А.И. Воробьева. М 2007: 465-486.
  45. Miyahara M., Shimamoto Y., Yamada H. et al. Cytomegalovirus-associated myelodysplasia and thrombocytopenia in an immunocompetent adult. Ann Hematol 1997; 74 (2): 99-101.
  46. Mizutani K., Azuma E., Komada Y. et al. An infantile case of cytomegalovirus induced idiopathic thrombocytopenic purpura with predominant proliferation of CD10 positive lymphoblast in bone marrow. Acta Paediatr Jpn 1995; 37 (1): 71-74.
  47. Гармаева Т.Ц., Куликов С.М., Карякин А.В. и др. Мониторирование факторов риска и индикаторов инфицированности вирусами гепатитов В и С гематологических больных. Гематол и трансфузиол 2006; 1: 23-27.
  48. Февралева И.С., Глинщикова О.А., Элижбаева М.А. и др. Распространенность парвовируса В19 среди больных гематологического стационара. Гематол и трансфузиол 2011; 6: 24-28.
  49. Гайдамака Н.В., Паровичникова Е.Н., Завалишина Л.Э. и др. Длительные аплазии костного мозга после химиотерапии у больных острыми лейкозами. Тер арх 2010; 7: 12-18.
  50. Heegaard E.D., Brown K.E. Human parvovirus B19. Clin Microbiol Rev 2002; 15: 485-505.
  51. Slavov S.N., Kashima S., Pinto A.C., Covas D.T. Human parvovirus B19: general considerations and impact on patients with sickle-cell disease and thalassemia and on blood transfusions. FEMS Immunol Med Microbiol 2011; 3 (62): 247-262.
  52. Carpenter S.L., Zimmerman S.A., Ware R.E. Acute parvovirus B19 infection mimicking congenital dyserythropoietic anemia. J Pediatr Hematol Oncol 2004; 26: 133-135.
  53. Weiland H.T., Salimans M.M., Fibbe W.E. et al. Prolonged parvovirus B19 infection with severe anaemia in a bone marrow transplant patient. Br J Haematol 1989; 71: 300.
  54. Solano C., Juan O., Gimeno C., Garcia-Conde J. Engraftment failure associated with peripheral blood stem cell transplantation after B19 parvovirus infection. Blood 1996; 88: 1515-1517.
  55. Azzi A., Fanci R., Ciappi S. et al. Human parvovirus B19 infection in bone marrow transplantation patients. Am J Hematol 1993; 44: 207-209.
  56. Broliden K. Parvovirus B19 infection in pediatric solid-organ and bone marrow transplantation. Pediatr Transplant 2001; 5: 320-330.
  57. Frickhofen N., Arnold R., Hertenstein B. et al. Parvovirus B19 infection and bone marrow transplantation. Ann Hematol 1992; 64 (Suppl): A121-124.
  58. Niitsu H., Takatsu H., Miura I. et al. Pure red cell aplasia induced by B19 parvovirus during allogeneic bone marrow transplantation. Rinsho Ketsueki 1990; 31: 1566-1571.
  59. Гармаева Т.Ц. Вирусные гепатиты В и С у больных заболеваниями системы крови: Автореф. дис. ... д-ра мед. наук. М 2012; 46.
  60. Савченко В.Г., Троицкая В.В., Мисюрин А.В. и др. Цитомегаловирусная инфекция у пациентов с гемобластозами Тер арх 2003; 7: 52-58.
  61. Miyahara M., Shimamoto Y., Yamada H. Cytomegalovirus-associated myelodysplasia and thrombocytopenia in an immunocompetent adult. Ann Hematol 1997; 74 (2): 99-101.
  62. Bain B.J. The haematological features of HIV infection. Br J Haematol 1997; 99: 1-8.
  63. Pande А., Bhattacharyya M., Pain S. Study of bone marrow changes in antiretroviral naive human immunodeficiency virus-infected anemic patients. Indian J Pathol Microbiol 2011; 54 (3): 542-546.
  64. Kopterides P., Halikias S., Tsavaris N. Visceral leishmaniasis masquerading as myelodysplasia. Am J Hematol 2003; 74: 198-199.
  65. Клясова Г.А. Рациональное лечение инфекционных осложнений цитостатической терапии в условиях иммуносупрессии. Вестн Московского онкологического общества 2009; 1: 5-8.
  66. Bernstein W.B., Trotta R.F., Rector J.T. et al. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother 2003; 37 (4): 517-520.
  67. Gerson S.L., Kaplan S.L., Bruss J.B. et al. Hematologic Effects of Linezolid: Summary of Clinical Experience. Antimicrob Agents Chemother. 2002; 46 (8): 2723-2726.
  68. Farber B.F., Moellering R.C. Retrospective Study of the Toxicity of Preparations of Vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 23 (1): 138-141.
  69. Rao N., Ziran B.H., Wagener M.M. et al. Similar Hematologic Effects of Long-Term Linezolid and Vancomycin Therapy in a Prospective Observational Study of Patients with Orthopedic Infections. Clin Infect Dis 2004; 38 (8): 1058-1064.
  70. Rouveix B., Lassoued K., Vittecoq D., Regnier B. Neutropenia due to beta lactamine antibodies. Br Med J (Clin Res Ed) 1983; 287 (6408): 1832-1834.
  71. Bernstein L.S. Adverse reactions to trimethoprim-sulfamethoxazole, with particular reference to long-term therapy. Can Med Assoc J 1975; 112 (13 Spec No): 96-98.
  72. Jewkes R.F., Edwards M.S., Grant B.J. Haematological changes in a patient on long-term treatment with a trimethoprim-sulphonamide combination. Postgrad Med J 1970; 46 (542): 723-726.
  73. Parmentier S., Schetelig J., Lorenz K. et al. Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors. Hematologica 2012; 97 (5): 723-730.
  74. Куликов С.М., Гармаева Т.Ц., Зингерман Б.В. и др. Вирусная безопасность гемотрансфузий и методы ее оценки. Гематол и трансфузиол 2008; 4: 3-5.
  75. Троицкая В.В. Диагностика и лечение цитомегаловирусной инфекции у больных гемобластозами: Автореф. дис. ... канд. мед. наук. М 2004.
  76. Lee S.H., Erber W.N., Porwit A. et al. ICSH guidelines for the standardization of bone marrow specimens and reports. Int J Lab Hematol 2008; 30 (5): 349-364.
  77. Bain B.J. Blood cells: a practical guide. 4th ed. Malden, Mass: Blackwell 2006.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies